C2 and Mr K discuss the recent executive order (because why go through the established US form of government when you can wage a war and impose tariffs without Congress or oversight), enacted on 4/20, which accelerates research and expands access to therapies for post-traumatic stress disorder (PTSD).
There was also a noticeable bump, on 4/20, for psychedelic drug manufacturers like:
Compass Pathways (CMPS), a biotech company and makers of COMP360 a magic mushroom-based drug that treats depression and is in phase 3 and phase 2 trials, hailing out of London, England, jumped as high as 53%.
Atai Beckley (ATAI), a clinical-stage biopharmaceutical company based out of New York, New York gained 37% at one point on 4/20.
Definium Therapeutics (DFTX), a clinical biopharmaceutical company developing drugs to combat anxiety disorder, major depressive and autism based out of New York, New York saw heights of 16%.
GH Research (GHRS), a clinical-stage biopharmaceutical company that develops treatments for depression and based out of Dublin, Ireland, rose as high as 34%.
Check out ZeroHedge at: https://www.zerohedge.com/ which provided a lot of the information for this podcast.
--
E-mail: 14theroadpodcast@gmail.com
Web Sites: https://14theroad.net
Facebook: Onefor TheRoad
X: #14theroadpodcast
YouTube: https://www.youtube.com/@sirrobinhood3409
Spotify: https://open.spotify.com/show/7tO982q90okkuSlPyRYFwg
Apple Podcasts - https://podcasts.apple.com/podcast/id1890917898
RSS: https://rss.com/podcasts/14theroad-podcast/
Podbean: https://jmkimball42.podbean.com
Amazon Music - https://music.amazon.com/podcasts/1996b910-30db-4cee-97a2-1c990df6922a/14theroad-podcast
zeno.fm: https://zeno.fm/podcast/14theroad-podcast/
Like us and subscribe on YouTube